Video

Dr. Iacovelli on the Rationale of the ARIES Trial in Urothelial Cancer

Roberto Iacovelli, MD, PhD, discusses the rationale of the phase 2 ARIES trial in urothelial cancer.

Roberto Iacovelli, MD, PhD, medical oncologist, the Fondazione Policlinico Gemelli IRCCS, Rome, Italy, discusses the rationale of the phase 2 ARIES trial (NCT03891238) in urothelial cancer.

Cisplatin-based chemotherapy remains the most recommended option for most patients with advanced urothelial cancer, Iacovelli says. However, about half of patients are ineligible to receive cisplatin-based chemotherapy, Iacovelli explains. Additionally, a subgroup of patients is ineligible for all forms of chemotherapy, Iacovelli adds.

The ARIES trial focused on the specific group of patients ineligible for cisplatin-based chemotherapy, Iacovelli continues. The goal of this study was to test the activity and safety of avelumab (Bavencio) in this patient population, Iacovelli concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity